Skip to Main Content
For healthcare professionals

DAREON®-5 Part 2: Indication-specific expansion cohort for DLL3/CD3 T-cell engager (obrixtamig) in patients with DLL3-high epNEC (NCT05882058)1

DLL3/CD3 T-cell engager DAREON®-5, NCT05882058
DLL3/CD3 T-cell engager DAREON®-5, NCT05882058

CD3, cluster of differentiation 3; DC, disease control; DLL3, delta-like canonical Notch ligand 3; DoR, duration of response; epNEC, extrapulmonary neuroendocrine carcinoma; OR, objective response; OS, overall survival; PFS, progression-free survival; PRO, patient-reported outcome; TEAE, treatment-emergent adverse event.

DAREON®-5 website: https://pro.boehringer-ingelheim.com/therapeutic-areas/oncology/dareon-5-trial/ 

References

  1. ClinicalTrials.gov. NCT05882058. https://clinicaltrials.gov/ct2/show/NCT05882058 (Accessed: September 2025).